17:41 , Jan 11, 2019 |  BC Week In Review  |  Clinical News

Autolus' dual targeting CAR T safe in Phase I/II data for hematological malignancies

Autolus Therapeutics plc (NASDAQ:AUTL) reported preliminary data from a pair of open-label, U.K. Phase I/II trials showing that AUTO3 had a manageable safety profile and led to responses among patients with hematological malignancies. AUTO3 comprises...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
20:22 , Oct 2, 2018 |  BC Extra  |  Preclinical News

Carl June, NIBR teams document CAR T resistance

A pair of Nature Medicine studies from CAR T pioneer Carl June and Novartis Institutes for BioMedical Research (NIBR) documented mechanisms that resulted in resistance to Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) or its...
19:32 , Jun 15, 2018 |  BC Week In Review  |  Financial News

Autolus proposes IPO terms

Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ. In a regulatory filing June 8, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS...
13:09 , Jun 8, 2018 |  BC Extra  |  Financial News

Autolus proposes IPO terms

Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ. In a regulatory filing Friday, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS representing...
21:36 , Sep 29, 2017 |  BC Week In Review  |  Financial News

CAR T company Autolus raises $80M series C

On Sept. 26, chimeric antigen receptor (CAR) T cell therapy company Autolus Ltd. (London, U.K.) raised $80 million in a series C round from new investors Cormorant Asset Management and Nextech Invest and existing investors...
21:18 , Sep 29, 2017 |  BioCentury  |  Finance

Fueling up

While crossovers joining Autolus Ltd. ’s series C round don’t necessarily mean the chimeric antigen receptor T cell therapy company will follow fellow Syncona Ltd. (LSE:SYNC) portfolio company Nightstar Therapeutics plc (NASDAQ:NITE) to NASDAQ anytime...
22:58 , Sep 26, 2017 |  BC Extra  |  Financial News

Autolus raises $80M series C

Chimeric antigen receptor (CAR) T cell therapy company Autolus Ltd. (London, U.K.) raised $80 million in a series C round from new investors Cormorant Asset Management and Nextech Invest and existing investors Syncona Ltd., Woodford...